Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05804825 · ClinicalTrials.gov registry record · NA
Testing the Persuasiveness of Pro-inoculation Arguments
A NA study of Vaccine Refusal and Human Papillomavirus Vaccination, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 523
- Enrollment target
- 1
- Study location
NCT05804825: Completed NA study of Vaccine Refusal and Human Papillomavirus Vaccination, sponsored by University of Pennsylvania.
NCT05804825 is a NA study of Vaccine Refusal and Human Papillomavirus Vaccination that has completed, run by University of Pennsylvania. The registered enrollment target is 523 participants, below the 1,213-participant average among 5 other Vaccine Refusal trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05804825, a NA study of Vaccine Refusal and Human Papillomavirus Vaccination, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 523 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will recruit a national sample of parents of 7-10-year-olds to complete an argument strength ranking for either a simple forwarding message or between 3 and 6 randomly selected arguments from an overall set of 50 to 100 messages identified from various online sources. Parents will rate each message they see on measures of perceived argument strength/PME. Parents will also answer sociodemographic questions and then rank the believability of a set of anti-vaccine messages identified in a different study. Study findings will contribute valuable information to understanding the effectiveness of different inoculation messages.
Primary Outcome
Arguments will be rated for their argument strength/message effectiveness
Conditions Studied
Interventions
- BEHAVIORAL Argument inoculation messages
- BEHAVIORAL Simple forewarning message
Study Locations (1)
Pennsylvania
- UPenn - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 523 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2023-05-24 |
| Phase | NA |
What the finished NCT05804825 record still lists
NCT05804825 is an interventional study that assigns participants to a tested intervention. The registered 523 participants enrollment target is mid-sized for trials with a published cap, below the 1,213-participant average among 5 other Vaccine Refusal trials with a reported enrollment target (57% lower).
The record links to 3 conditions, with Vaccine Refusal appearing as the primary indexed condition, and to 2 interventions - of which Argument inoculation messages is the first listed.
NCT05804825 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05804825 about?
NCT05804825 is a clinical study titled "Testing the Persuasiveness of Pro-inoculation Arguments". The investigators will recruit a national sample of parents of 7-10-year-olds to complete an argument strength ranking for either a simple forwarding message or between 3 and 6 randomly selected arguments from an overall set of 50 to 100 messages identified from various online sources. Parents will ...
What is the current status of trial NCT05804825?
This trial is currently completed. It is a NA study. The enrollment target is 523 participants. The study started on 2023-05-04. Estimated completion is 2023-05-24.
What conditions does trial NCT05804825 study?
This clinical trial studies the following conditions: Vaccine Refusal, Human Papillomavirus Vaccination, Vaccination Hesitancy.
What interventions are being tested in trial NCT05804825?
The interventions under investigation include: Argument inoculation messages (BEHAVIORAL), Simple forewarning message (BEHAVIORAL).
Who is sponsoring clinical trial NCT05804825?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05804825 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaccine Refusal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Vaccine Acceptance Through EHR Integrated Patient- and Provider-Facing Decision Support
RECRUITING · NA
-
Improving Vaccine Counseling Skills Among Residents Using Educational Modules and Standardized Patient Encounters
COMPLETED · NA
-
Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19
COMPLETED · NA
-
Vaccine Confidence Study Among Historically Marginalized Racial and Ethnic Groups
RECRUITING
-
Vaccine Hesitancy: A Survey of Pediatric Clinicians
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03526835 · 523 participants · Phase 1
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- NCT04580134 · 524 participants · Phase 4
CLOZAPINE Response in Biotype-1
- NCT07158814 · 524 participants · Phase 4
Safety of RSV Preventive Monoclonal Antibody
- NCT06835686 · 522 participants · NA
Collaborative Multi-level Obesity Intervention Engaging Underserved Communities Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI